Aarti Pharmalabs Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Aarti Pharmalabs Ltd filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Aarti Pharmalabs reported Q1 FY27 standalone revenue of Rs 535 crore, up 42% year-on-year, with EBITDA of Rs 133 crore and profit after tax of Rs 71 crore. Management attributed the growth to record Xanthine derivatives sales driven by higher realizations amid raw material cost increases linked to the Middle East crisis, while the API and CDMO segments saw more modest contributions of 30% and 7% of revenue respectively. Management also discussed capacity expansions including completion of steroid block debottlenecking at Tarapur, commercialization of additional Xanthine capacity, and a new Rs 149 crore capex for a dedicated CDMO block at Atali.
Numbers mentioned
Revenue: INR535 crores (Q1 FY27)
p. 3
“The top line was INR535 crores as compared to INR375 crores a year back, showing an increase of 42% Y-o-Y.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
EBITDA: INR133 crores (Q1 FY27)
p. 3
“The EBITDA was INR133 crores as compared to INR95 crores in the corresponding period of the previous year.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
Profit after tax: INR71 crores (Q1 FY27)
p. 3
“The profit after tax for the Q1 FY '27 was INR71 crores as compared to INR48 crores a year back, which was 49% increase Y-o-Y.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
Xanthine Derivatives share of turnover: 57% (Q1 FY27)
p. 3
“Xanthine Derivatives segment contributed to 57% of our turnover in this current quarter and it recorded the highest ever quarterly sales of Xanthine derivatives.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
API and Intermediate share of turnover: 30% (Q1 FY27)
p. 3
“The API and Intermediate business stood at 30% of the turnover.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
CDMO/CMO share of revenue: 7% (Q1 FY27)
p. 3
“The third segment, CDMO/CMO, has contributed to 7% of the revenue in this quarter.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
Number of active CDMO customers: 22 (Q1 FY27)
p. 3
“We are presently working with 22 customers and the number of active projects is now 57, of which 37 projects are in the commercial stages, while 20 are under different developmental stages”
Rashesh Gogri, page 3 of the filed PDF · View the filing
Steroidal capacity enhancement: 33% (Q1 FY27)
p. 4
“As a result, now we have an additional 33% of our existing steroidal capacity enhanced for this block.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
Atali Block 2 capex: INR 149 crores
p. 4
“Additionally, we have announced a capex of INR 149 crores towards Block 2 at Atali with 400+ kL reactor capacity.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Xanthine capacity utilization — 80% plus capacity utilization · FY28
stated firmly by Rashesh Gogri
p. 4
“The incremental capacity will be ramped up through the next few quarters and we can reach 80% plus capacity utilization by FY '28.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
Atali Block 1 operational status — fully operational · Q2 FY27
stated firmly by Rashesh Gogri
p. 4
“Both phases of Atali Block 1 with 440 kL reactor capacity will become fully operational in Q2 FY '27.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
Atali Block 2 groundbreaking and completion — Q3 FY27, 12-15 months completion
stated firmly by Rashesh Gogri
p. 4
“Groundbreaking is expected in Q3 FY '27 and the completion time line is around 12 to 15 months.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
Global market share in Xanthine — 20% to 25% global market share · next 2 years
stated as an aspiration by Rashesh Gogri
p. 5
“So we are aiming towards 20% to 25% global market share with the enhanced capacity in the next 2 years' time.”
Rashesh Gogri, page 5 of the filed PDF · View the filing
Company-level EBITDA margin — 20% to 25% · FY27
stated firmly by Piyush Lakhani
p. 10
“But we are still guiding for EBITDA margin of anywhere between 22% and 25% for the full year on our stand-alone financials.”
Piyush Lakhani, page 10 of the filed PDF · View the filing
CDMO/CMO revenue growth — 40% to 50% growth · current financial year
stated firmly by Rashesh Gogri
p. 9
“That's why we have guided for a 40% to 50% growth, and we are quite confident that we will achieve that growth in this current financial year.”
Rashesh Gogri, page 9 of the filed PDF · View the filing
CDMO/CMO revenue target — INR1,000 crores
stated as an aspiration by Rashesh Gogri
p. 9
“We are quite confident of the INR1,000 crores target that we have set for us.”
Rashesh Gogri, page 9 of the filed PDF · View the filing
Xanthine revenue for the year — INR900 crores to INR1,100 crores · FY27
stated conditionally by Rashesh Gogri
p. 11
“We have to wait and see how the prices normalizes. That will have a bearing on overall pricing. But it will be a range between INR900 crores to INR1,100 crores.”
Rashesh Gogri, page 11 of the filed PDF · View the filing
API and Intermediate revenue — nearly INR780 crores level · FY27
stated as an aspiration by Rashesh Gogri
p. 11
“Yes. I think the revenue -- internal target is to meet that number. But I think looking at the overall environment and the launches, I think we'll be not able to cross it, but nearly there.”
Rashesh Gogri, page 11 of the filed PDF · View the filing
API business revenue range — INR170 crores to INR190 crores
stated firmly by Rashesh Gogri
p. 20
“Yes, yes, we should be in that range of INR170 crores to INR190 crores, anything in that range going forward.”
Rashesh Gogri, page 20 of the filed PDF · View the filing
API revenue target — INR1,000 crores plus
stated as an aspiration by Rashesh Gogri
p. 20
“No. We won't need any more capex for that. I think we will be good for INR1,000 crores plus with the current debottlenecking exercise that we have done for steroids and ongoing exercise for anticancer products.”
Rashesh Gogri, page 20 of the filed PDF · View the filing
CDMO/CMO share of company sales — beyond 25-30% overall percentage
stated as an aspiration by Rashesh Gogri
p. 14
“With all the 3 segments breaching that, I think we expect CDMO/CMO segment to go beyond 25-30% overall percentage of the company's sales going forward.”
Rashesh Gogri, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Export share is 79-80%, expected to remain higher going forward; company targets 20-25% global market share within two years with enhanced capacity.
Answered by Rashesh Gogri
Asked by Dhruv: What is the current Xanthine domestic vs export revenue split and outlook for global market share?
p. 4
“No. Our current split in the current quarter is 80%, 79% export and 21% local revenue share.”
Rashesh Gogri, page 4 of the filed PDF · View the filing
Volume growth was 25% over last year, with realization normalizing.
Answered by Rashesh Gogri
Asked by Raj Agarwal: What was the volume growth versus realization growth in Xanthine compared to last year?
p. 5
“Yes. 25% is the volume growth over last year's volume.”
Rashesh Gogri, page 5 of the filed PDF · View the filing
Management said absolute gross margin should sustain due to higher volumes even as per-unit margins normalize.
Answered by Rashesh Gogri
Asked by Ankit Gupta: Are the elevated gross and EBITDA margins from Xanthine sustainable given falling realizations?
p. 8
“That will be mitigated by the increased quantities that we'll start producing.”
Rashesh Gogri, page 8 of the filed PDF · View the filing
Yes, removal of export rebates has structurally increased Xanthine prices and helped margins.
Answered by Rashesh Gogri
Asked by Ankit Gupta: Has China's anti-involution policy impacted Xanthine pricing?
p. 8
“Yes, yes. In Xanthine also, they have removed the rebate and due to which structurally the prices of Xanthine have anyway increased overall because they are not able to get the rebate.”
Rashesh Gogri, page 8 of the filed PDF · View the filing
Management maintained guidance of 22-25% EBITDA margin for the full year.
Answered by Piyush Lakhani
Asked by Umang Gada: Where will full-year EBITDA margins land given falling Xanthine prices and Atali pre-op expenses?
p. 10
“But we are still guiding for EBITDA margin of anywhere between 22% and 25% for the full year on our stand-alone financials.”
Piyush Lakhani, page 10 of the filed PDF · View the filing
Management estimated roughly a 50-50 split between structural and temporary factors.
Answered by Rashesh Gogri
Asked by Shubham Aggarwal: How much of the Xanthine price increase is structural versus temporary?
p. 15
“I think it is very difficult to put that number, but I think we can go by 50-50.”
Rashesh Gogri, page 15 of the filed PDF · View the filing
Management attributed it to timing of shipments and postponements, and reaffirmed full-year growth guidance.
Answered by Rashesh Gogri
Asked by Julie Mehta: Why did CDMO revenue decline this quarter, and is the 40-50% growth guidance still intact?
p. 18
“CDMO, we have guided and we are continuing to hold on our guidance of 40-50% growth over last year.”
Rashesh Gogri, page 18 of the filed PDF · View the filing
Asset turnover expected around 1x, with meaningful utilization building up over 1-1.5 years after commissioning at the end of next financial year.
Answered by Rashesh Gogri
Asked by Pritesh Chheda: What is the expected ramp-up and asset turnover for the new dedicated CDMO capex?
p. 17
“Yes. Asset turnover will be in excess of -- around 1x.”
Rashesh Gogri, page 17 of the filed PDF · View the filing
Risks flagged
Pricing pressure in existing API molecules
p. 3
“While we are working on the development of new molecules with the medium-term patent expiry, the pricing pressures in existing molecules remain.”
Rashesh Gogri, page 3 of the filed PDF · View the filing
Raw material cost volatility from the Middle East crisis affecting margins
p. 5
“And you have seen in the current volatility with this crisis of Middle East increased the raw material prices and which we have passed on to our customers.”
Rashesh Gogri, page 5 of the filed PDF · View the filing
Declining Xanthine realizations as raw material prices normalize
p. 6
“Realization per kg will decline. But overall, with the additional capacity, our sales will grow.”
Rashesh Gogri, page 6 of the filed PDF · View the filing
Strong competition from China in Xanthine chemistry
p. 5
“China is a major competitor for Xanthine. I think the overall capacity of Xanthine chemistry in China is quite significant.”
Rashesh Gogri, page 5 of the filed PDF · View the filing
Pricing pressure on lifestyle drug launches in API segment
p. 19
“But due to the launch, there is strong pressure on the pricing.”
Rashesh Gogri, page 19 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.